Sequence heterogeneity and viral dynamics in cerebrospinal fluid and plasma during antiretroviral therapy

References

• Chien JW, Valdez H, McComsey G, McClernon D, St Clair M, Lederman MM (1999). Presence of mutation conferring resistance to lamivudine in plasma and cerebrospinal fluid of HIV-1-infected patients. J Acquir Immune Defic Syndr 21: 277–280.
   Google Scholar
• Cinque P, Presi S, Bestetti A, Pierotti C, Racca S, Boeri E, Morelli P, Carrera, P, Ferrari M, Lazzarin A (2001). Effect of genotypic resistance on the virological response to highly active antiretroviral therapy in cerebrospinal fluid. AIDS Res Human Retrovirus 17: 377–383.
   PubMed Web of Science ®Google Scholar
• Di Stefano M, Sabri F, Leitner T, Svennerholm B, Hagberg L, Norkrans G, Chiodi F (1995). Reverse transcriptase sequence of paired isolates of cerebrospinal fluid and blood from patients infected with human immunodeficiency virus type 1 during zidovudine treatment. J Clin Microbiol 33: 352–355.
   PubMed Web of Science ®Google Scholar
• Drewe J, Gutmann H, Fricker G, Torok M, Beglinger C, Huwyler J (1999). HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833. Biochem Pharmacol 57: 1147–1152.
   PubMed Web of Science ®Google Scholar
• Ellis RJ, Gamst AC, Capparelli E, Spector SA, Hsia K, Wolfson T, Abramson I Grant I, McCutchan JA (2000). Cerebrospinal fluid HIV RNA originates from both local CNS and systemic sources. Neurology 54: 927–936.
   PubMed Web of Science ®Google Scholar
• Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chave JP, Decosterd LA, Furrer H, Opravil M, Pantaleo G, Retelska D, Ruiz L, Schinkel AH, Vernazza P, Eap CB, Telenti A, The Swiss HIV Cohort Study (2002). Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 359: 30–36.
   PubMed Web of Science ®Google Scholar
• Gartner S (2000). HIV infection and dementia. Science 287: 602–604.
   PubMed Web of Science ®Google Scholar
• Gisolf EH, Enting RH, Jurriaans S, de Wolf F, Van der Ende ME, Hoetelmans RM, Portegies P, Danner SA (2000). Cerebrospinal fluid HIV-1 RNA during treatment with ritonavir/saquinavir or ritonavir/saquinavir/stavudine. AIDS 14: 1583–1589.
   PubMed Web of Science ®Google Scholar
• Haas DW, Clough LA, Johnson B, Harris VL, Spearman P, Wilkinson GR, Fletcher CV, Fiscus S, Raffanti S, Donlon R, McKinsey J, Nicotera J, Schmidt D, Shoup RE, Kates RE, Lloyd RMJ, Larder B (2000a). Evidence for a source of HIV-1 within the central nervous system by ultra-intensive sampling of cerebrospinal fluid and plasma. AIDS Res Human Retrovirus 16: 1491–1502.
   PubMed Web of Science ®Google Scholar
• Haas DW, Johnson B, Nicotera J, Bailey DG, Harris VL, Bowles F, Raffanti S, Finn T, Schranz J, Saah, AJ, Stone J (2002). Steady-state indinavir (Crixivan[sup]®[/sup]) pharmacokinetics in cerebrospinal fluid (CSF) and plasma in patients receiving low-dose ritonavir (Norvir), as determined by ultra-intensive CSF sampling. Presented at 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, February, 2002.
   Google Scholar
• Haas DW, Stone J, Clough LA, Johnson B, Spearman P, Harris VL, Nicotera J, Johnson RH, Raffanti S, Zhong L, Bergqwist P, Chamberlin S, Hoagland V, Ju WD (2000b). Steady-state pharmacokinetics of indinavir in cerebrospinal fluid and plasma among adults with human immunodeficiency virus type 1 infection. Clin Pharmacol Ther 68: 367–374.
   PubMed Web of Science ®Google Scholar
• Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M (1995). Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373: 123–126.
   PubMed Web of Science ®Google Scholar
• Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U (2000). Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 97: 3473–3478.
   PubMed Web of Science ®Google Scholar
• Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM, Wilkinson GR (1998). The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 101: 289–294.
   PubMed Web of Science ®Google Scholar
• Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, Taylor A, Xie HG, McKinsey J, Zhou S, Lan LB, Schuetz JD, Schuetz EG, Wilkinson GR (2001). Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 70: 189–199.
   PubMed Web of Science ®Google Scholar
• McCoig C, Castrejon MM, Castano E, De Suman O, Baez C, Redondo W, McClernon D, Danehower S, Lanier ER, Richardson C, Keller A, Hetherington S, Saez-Llorens X, Ramilo O (2002). Effect of combination antiretroviral therapy on cerebrospinal fluid HIV RNA, HIV resistance, and clinical manifestations of encephalopathy. J Pediatrics 141: 36–44.
   PubMed Web of Science ®Google Scholar
• Tang YW, Huong JT, Lloyd RMJ, Spearman P, Haas DW (2000). Comparison of human immunodeficiency virus type 1 RNA sequence heterogeneity in cerebrospinal fluid and plasma. J Clin Microbiol 38: 4637–4639.
   PubMed Web of Science ®Google Scholar
• Tashima KT, Flanigan TP, Kurpewski J, Melanson SM, Skolnik PR (2002). Discordant human immunodeficiency virus type 1 drug resistance mutations, including K103N, observed in cerebrospinal fluid and plasma. Clin Infect Dis 35: 82–83.
   Google Scholar
• Venturi G, Catucci M, Romano L, Corsi P, Leoncini F, Valensin PE, Zazzi M (2000). Antiretroviral resistance mutations in human immunodeficiency virus type 1 reverse transcriptase and protease from paired cerebrospinal fluid and plasma samples. J Infect Dis 181: 740–745.
   PubMed Web of Science ®Google Scholar